Paco E Bravo1, Ganesh Raghu2, David G Rosenthal3, Shana Elman4, Bradley J Petek5, Laurie A Soine6, Jeffrey H Maki4, Kelley R Branch7, Sofia C Masri7, Kristen K Patton7, James H Caldwell6, Eric V Krieger7. 1. Division of Cardiology, University of Washington School of Medicine, Seattle, WA, United States; Noninvasive Cardiovascular Imaging Program, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: pbravo@bwh.harvard.edu. 2. Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, WA, United States. 3. Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. 4. Department of Radiology, University of Washington School of Medicine, Seattle, WA, United States. 5. University of Washington School of Medicine, Seattle, WA, United States. 6. Division of Cardiology, University of Washington School of Medicine, Seattle, WA, United States; Department of Radiology, University of Washington School of Medicine, Seattle, WA, United States. 7. Division of Cardiology, University of Washington School of Medicine, Seattle, WA, United States.
Abstract
BACKGROUND: Prior studies have shown that late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) and fluorodeoxyglucose (FDG) positron emission tomography (PET) confer incremental risk assessment in patients with cardiac sarcoidosis (CS). However, the incremental prognostic value of the combined use of LGE and FDG compared to either test alone has not been investigated, and this is the aim of the present study. METHODS: Retrospective observational study of 56 symptomatic patients with high clinical suspicion for CS who underwent LGE-CMR and FDG-PET and were followed for the occurrence of death and/or malignant ventricular arrhythmias (VA). RESULTS: The combination of PET and CMR yielded the following groups: 1) LGE-negative/normal-PET (n=20), 2) LGE-positive/abnormal-FDG (n=20), and 3) LGE-positive/normal FDG (n=16). After a median follow-up of 2.6years (IQR 1.2-4.1), 16 patients had events (7 deaths, 10 VA). All, but 1, events occurred in patients with LGE. LGE-positive/abnormal-FDG (7 events, HR 10.1 [95% CI 1.2-84]; P=0.03) and LGE-positive/normal-FDG (8 events, HR 13.3 [1.7-107]; P=0.015) patients had comparable risk of events compared to the reference LGE-negative/normal-PET group. In adjusted Cox-regression analysis, presence of LGE (HR 18.1 [1.8-178]; P=0.013) was the only independent predictor of events. CONCLUSION: CS patients with LGE alone or in association with FDG were at similar risk of future events, which suggests that outcomes may be driven by the presence of LGE (myocardial fibrosis) and not FDG (inflammation).
BACKGROUND: Prior studies have shown that late gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) and fluorodeoxyglucose (FDG) positron emission tomography (PET) confer incremental risk assessment in patients with cardiac sarcoidosis (CS). However, the incremental prognostic value of the combined use of LGE and FDG compared to either test alone has not been investigated, and this is the aim of the present study. METHODS: Retrospective observational study of 56 symptomatic patients with high clinical suspicion for CS who underwent LGE-CMR and FDG-PET and were followed for the occurrence of death and/or malignant ventricular arrhythmias (VA). RESULTS: The combination of PET and CMR yielded the following groups: 1) LGE-negative/normal-PET (n=20), 2) LGE-positive/abnormal-FDG (n=20), and 3) LGE-positive/normal FDG (n=16). After a median follow-up of 2.6years (IQR 1.2-4.1), 16 patients had events (7 deaths, 10 VA). All, but 1, events occurred in patients with LGE. LGE-positive/abnormal-FDG (7 events, HR 10.1 [95% CI 1.2-84]; P=0.03) and LGE-positive/normal-FDG (8 events, HR 13.3 [1.7-107]; P=0.015) patients had comparable risk of events compared to the reference LGE-negative/normal-PET group. In adjusted Cox-regression analysis, presence of LGE (HR 18.1 [1.8-178]; P=0.013) was the only independent predictor of events. CONCLUSION:CSpatients with LGE alone or in association with FDG were at similar risk of future events, which suggests that outcomes may be driven by the presence of LGE (myocardial fibrosis) and not FDG (inflammation).
Authors: Saurabh Kumar; Chirag Barbhaiya; Koichi Nagashima; Eue-Keun Choi; Laurence M Epstein; Roy M John; Melanie Maytin; Christine M Albert; Amy L Miller; Bruce A Koplan; Gregory F Michaud; Usha B Tedrow; William G Stevenson Journal: Circ Arrhythm Electrophysiol Date: 2014-12-19
Authors: Yuji Okura; G William Dec; Joshua M Hare; Makoto Kodama; Gerald J Berry; Henry D Tazelaar; Kent R Bailey; Leslie T Cooper Journal: J Am Coll Cardiol Date: 2003-01-15 Impact factor: 24.094
Authors: Jordana Kron; William Sauer; Joseph Schuller; Frank Bogun; Thomas Crawford; Sinan Sarsam; Lynda Rosenfeld; Teferi Y Mitiku; Joshua M Cooper; Davendra Mehta; Arnold J Greenspon; Matthew Ortman; David B Delurgio; Ravinder Valadri; Calambur Narasimhan; Nalla Swapna; Jagmeet P Singh; Stephan Danik; Steven M Markowitz; Adrian K Almquist; Andrew D Krahn; Luke G Wolfe; Shawn Feinstein; Kenneth A Ellenbogen Journal: Europace Date: 2012-09-21 Impact factor: 5.214
Authors: Klaus Strobel; Matthias Rüdy; Valerie Treyer; Patrick Veit-Haibach; Cyrill Burger; Thomas F Hany Journal: Nucl Med Commun Date: 2007-07 Impact factor: 1.690
Authors: Ron Blankstein; Michael Osborne; Masanao Naya; Alfonso Waller; Chun K Kim; Venkatesh L Murthy; Pedram Kazemian; Raymond Y Kwong; Michifumi Tokuda; Hicham Skali; Robert Padera; Jon Hainer; William G Stevenson; Sharmila Dorbala; Marcelo F Di Carli Journal: J Am Coll Cardiol Date: 2013-10-16 Impact factor: 24.094
Authors: Kalie Y Kebed; Spencer V Carter; Erin Flatley; R Parker Ward; Joshua D Moss; Daniel E Appelbaum; Amita Singh; Roberto M Lang; Roderick Tung; Amit R Patel Journal: Int J Cardiovasc Imaging Date: 2020-11-22 Impact factor: 2.357
Authors: David G Rosenthal; Purvi Parwani; Tyler O Murray; Bradley J Petek; Bryan S Benn; Teresa De Marco; Edward P Gerstenfeld; Munir Janmohamed; Liviu Klein; Byron K Lee; Joshua D Moss; Melvin M Scheinman; Henry H Hsia; Van Selby; Laura L Koth; Miguel H Pampaloni; Julie Zikherman; Vasanth Vedantham Journal: J Am Heart Assoc Date: 2019-09-06 Impact factor: 5.501
Authors: Elliott D Crouser; Mark W Julian; Sabahattin Bicer; Vikas Ghai; Taek-Kyun Kim; Lisa A Maier; May Gillespie; Nabeel Y Hamzeh; Kai Wang Journal: PLoS One Date: 2021-01-26 Impact factor: 3.240
Authors: Maria Giovanna Trivieri; Paolo Spagnolo; David Birnie; Peter Liu; Wonder Drake; Jason C Kovacic; Robert Baughman; Zahi A Fayad; Marc A Judson Journal: J Am Coll Cardiol Date: 2020-10-20 Impact factor: 24.094
Authors: Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman Journal: Am J Respir Crit Care Med Date: 2020-04-15 Impact factor: 21.405